Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452279 · ClinicalTrials.gov registry record · NA
Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification
A NA study, sponsored by Vance Thompson Vision.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT04452279: Completed NA study, sponsored by Vance Thompson Vision.
NCT04452279 is a NA study that has completed, run by Vance Thompson Vision. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452279, a NA study, has completed, sponsored by Vance Thompson Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
This prospective interventional single-arm trial evaluates measures changes in ocular surface disease parameters in eyes with mild to moderate open-angle glaucoma (OAG) on 1-4 glaucoma medications who undergo phacoemulsification and trabecular micro-bypass stent(s) implantation (iStent or iStent inject).
Primary Outcome
Difference between preoperative and Month 3 mean OSDI score
Interventions
- DEVICE iStent or iStent inject implantation with concomitant cataract surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2019-08-15 |
| Phase | NA |
What the finished NCT04452279 record still lists
NCT04452279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which iStent or iStent inject implantation with concomitant cataract surgery is the first listed.
NCT04452279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04452279 about?
NCT04452279 is a clinical study titled "Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification". This prospective interventional single-arm trial evaluates measures changes in ocular surface disease parameters in eyes with mild to moderate open-angle glaucoma (OAG) on 1-4 glaucoma medications who undergo phacoemulsification and trabecular micro-bypass stent(s) implantation (iStent or iStent inj...
What is the current status of trial NCT04452279?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2018-05-01. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT04452279?
The interventions under investigation include: iStent or iStent inject implantation with concomitant cataract surgery (DEVICE).
Who is sponsoring clinical trial NCT04452279?
This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04452279's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI